Solvonis Therapeutics Plc

As of December 31, 2025, Solvonis Therapeutics Plc carries a market capitalization of 2.11B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Solvonis Therapeutics Plc's next confirmed earnings release is scheduled for June 30, 2027.

As of December 31, 2025, Solvonis Therapeutics Plc has 6.81B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Solvonis Therapeutics Plc maintains a current ratio of 4.00, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Solvonis Therapeutics Plc's stock has declined approximately 71.21% over the past 52 weeks. The 50-day moving average sits at 0.12, while the 200-day moving average is 0.20.

As of December 31, 2025, Solvonis Therapeutics Plc holds 172.00M in cash and equivalents against 7.50M in total debt, resulting in a net debt position of -164.50M. Total book value stands at 619.10M, with working capital of 143.80M providing operational flexibility.